Guillermo Crespo1, Paula Jiménez-Fonseca2, Ana Custodio3, Carlos López4, Alberto Carmona-Bayonas5, Vicente Alonso6, Miguel Navarro7, Javier Aller8, Isabel Sevilla9, Enrique Grande10, Pablo Gajate10, Teresa Alonso-Gordoa10, Ignacio Matos11, Jaume Capdevila11, Beatriz Nieto12, Jorge Barriuso13. 1. Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain. 2. Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain. 3. Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain. 4. Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 5. Department of Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain. 6. Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain. 7. Department of Medical Oncology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain. 8. Endocrinology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain. 9. Department of Medical Oncology, Hospital Clínico Virgen de la Victoria y Regional de Málaga, Málaga, Spain. 10. Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. 11. Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Universitat Autónoma de Barcelona, Barcelona, Spain. 12. Department of Medical Oncology, Hospital Universitario de León, León, Spain. 13. Department of Medical Oncology, University of Manchester, Manchester, UK.
Abstract
BACKGROUND & METHODS: Capecitabine and temozolomide chemotherapy was used in 65 patients with grade 1/2 neuroendocrine tumors (NETs). 46 patients (70.8%) had pancreatic NETs (pNETs). RESULTS: Response rate was 47.7%, with two complete responses (3.1%), 29 partial responses (44.6%) and 27 patients (41.5%) achieved stable disease. Median progression-free survival was 16.1 months (95% CI: 10.7-21.6) and overall survival was 38.3 months (95% CI: 24.6-51.9). Differences in progression-free survival and overall survival between pNETs and non-pNETs were not found. Nine (13.8%) patients experienced grade 3/4 toxicities, mainly thrombocytopenia (10.8%) and neutropenia (7.7%). CONCLUSION: This is the largest reported series of NETs treated with capecitabine and temozolomide in daily practice and shows that this combination is a promising treatment option for both grade 1/2 pNETs and non-pNETs.
BACKGROUND & METHODS:Capecitabine and temozolomide chemotherapy was used in 65 patients with grade 1/2 neuroendocrine tumors (NETs). 46 patients (70.8%) had pancreatic NETs (pNETs). RESULTS: Response rate was 47.7%, with two complete responses (3.1%), 29 partial responses (44.6%) and 27 patients (41.5%) achieved stable disease. Median progression-free survival was 16.1 months (95% CI: 10.7-21.6) and overall survival was 38.3 months (95% CI: 24.6-51.9). Differences in progression-free survival and overall survival between pNETs and non-pNETs were not found. Nine (13.8%) patients experienced grade 3/4 toxicities, mainly thrombocytopenia (10.8%) and neutropenia (7.7%). CONCLUSION: This is the largest reported series of NETs treated with capecitabine and temozolomide in daily practice and shows that this combination is a promising treatment option for both grade 1/2 pNETs and non-pNETs.
Authors: Louis de Mestier; Thomas Walter; Camille Evrard; Paul de Boissieu; Olivia Hentic; Jérôme Cros; David Tougeron; Catherine Lombard-Bohas; Vinciane Rebours; Pascal Hammel; Philippe Ruszniewski Journal: Neuroendocrinology Date: 2019-05-10 Impact factor: 4.914
Authors: Paula Espinosa-Olarte; Anna La Salvia; Maria C Riesco-Martinez; Beatriz Anton-Pascual; Rocio Garcia-Carbonero Journal: Rev Endocr Metab Disord Date: 2021-04-11 Impact factor: 9.306
Authors: Aman Chauhan; Zainab Farooqui; Le Aundra Murray; Heidi L Weiss; Zin War Myint; Arun Kumar A Raajasekar; B Mark Evers; Susanne Arnold; Lowell Anthony Journal: J Oncol Date: 2018-05-07 Impact factor: 4.375
Authors: Martina T Mogl; Eva M Dobrindt; Josephine Buschermöhle; Claudia Bures; Johann Pratschke; Holger Amthauer; Christoph Wetz; Henning Jann Journal: Visc Med Date: 2020-01-20